Articles tagged "Rejection"

2020 American Transplant Congress
Significance of Pathology in Antibody Mediated Rejection in Pediatric Kidney Transplant Recipients on 1 Year Outcomes: Interim Results of the Paramour “Pediatric Renal AMR Outcomes” Study
I. Ashoor¹, A. Jain², R. Garro³, M. Kallash⁴, S. Soloman⁵, K. Twombley⁶
¹LSUHSC and Children's Hospital New Orleans, New Orleans, LA, ²Children's Hospital of Michigan, Detroit, MI, ³Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Maria Fareri Children's Hospital at Westchester Medical Center, Valhalla, NY, ⁶Medical University of South Carolina, Charleston, SC
*Purpose: Little is known about how pathology findings on biopsy correlate with outcomes in pediatric kidney transplant patients with antibody mediated rejection (AMR). We aimed…
2020 American Transplant Congress
Single Center Experience in Using Donor-Derived Cell-Free DNA in Kidney Transplant
P. Homkrailas¹, S. Lee², B. Kandagedon¹, G. Danovitch¹, S. Bunnapradist¹
¹Medicine, Division of Nephrology, Kidney and Pancreas Transplant Programs, UCLA, Los Angeles, CA, ²Department of Pharmacy, UCLA, Los Angeles, CA
*Purpose: While the gold standard for diagnosing allograft rejection in kidney transplant recipients (KTX) continues to be histopathologic evaluation, it has been well recognized that…
2020 American Transplant Congress
Follow Up of Imlifidase (IdeS) Desensitized Kidney Transplant Recipients
S. C. Jordan¹, R. A. Montgomery², T. Lundgren³, C. Legendre⁴, N. Desai⁵, G. Eckerwall⁶, L. Laxmyr⁶, H. Olsson⁶, A. Runström⁶, Å. Schiött⁶, K. Sjöholm⁶, E. Sonesson⁶, L. Winstedt⁶, T. Lorant⁷, C. Kjellman⁶
¹Cedars Sinai Medical Center, Los Angeles, CA, ²NYU Langone Health Transplant Institute, New York, NY, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Hospital Necker & Paris Descartes University, Paris, France, ⁵Johns Hopkins University, Baltimore, MD, ⁶Hansa Biopharma AB, Lund, Sweden, ⁷Uppsala University, Uppsala, Sweden
*Purpose: 46 highly sensitized patients received kidney transplants after desensitization with imlifidase (currently under investigation) across four Phase 2 clinical trials, and 6-month safety and…
2020 American Transplant Congress
Reduced Dose of Mycophenolate Mofetil as Well as Preformed DSA Are Risk Factors Associated with the Development of Chronic Active Antibody Mediated Rejection after Kidney Transplantation: A Retrospective Case Control Study
K. Shinoda¹, H. Oguchi¹, K. Nishikawa¹, T. Yonekura¹, M. Muramatsu¹, T. Kawamura¹, Y. Hamasaki¹, T. Mikami², K. Sakai¹, S. Shishido¹
¹Toho University Faculty of Medicine, Tokyo, Japan, ²Pathology, Toho University Faculty of Medicine, Tokyo, Japan
*Purpose: The purpose of this study is to explore the risk factors associated with the development of chronic active antibody mediated rejection (CAAMR) after the…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA May Not Discriminate Rejection in Kidney Transplant Recipients with a Prior Allograft in Place
A. Vo, M. Gillespie, S. C. Jordan, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, E. Huang
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker discriminating rejection in kidney transplant (KTx) patients (pts). However, its performance when stratified by rejection risk…
2020 American Transplant Congress
Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients
H. Sasaki¹, T. Tanabe¹, H. Higuchi¹, T. Tsujimoto², H. Harada¹
¹Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan, ²Pharmacy, Sapporo City General Hospital, Sapporo, Japan
*Purpose: Everolimus (EVR) in combination with low-dose calcineurin inhibitor has been demonstrated in clinical trials to have comparable efficacy in low immunological risk kidney transplant…
2020 American Transplant Congress
Case Series of Belatacept for Calcineurin Inhibitor Sparing after Lung Transplantation
H. Patel, C. R. Ensor, R. D. Davis, L. Bogar, D. Colella, M. Kildea, J. Kim, A. Satterthwaite, D. Ventura, C. Gries
AdventHealth, Orlando, FL
*Purpose: Belatacept is a recombinant soluble fusion protein which selectively blocks T-cell co-stimulation. It received initial FDA approval for prophylaxis of organ rejection in Epstein-Barr…
2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
C. Schardt, R. Yau, A. Burgos, C. Tunwar
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…
2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
I. Revuelta¹, E. De Sousa-Amorim¹, M. Lozano², D. Cucchiari¹, J. Cid², L. Peri³, E. Palou⁴, M. Musquera³, J. Martorell⁵, J. M. Campistol¹, F. Oppenheimer¹, F. Diekmann¹
¹Renal Transplant Unit, Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain, ²Apheresis and Cellular Therapy Unit, Hospital Clinic, Barcelona, Spain, ³Department of Urology, Hospital Clinic, Barcelona, Spain, ⁴Histocompatibility Lab. Department of Immunology, Hospital Clinic, Barcelona, Spain, ⁵Histocompatibility Lab, Department of Immunology, Hospital Clinic, Barcelona, Spain
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…
2020 American Transplant Congress
Exosomes Containing Kidney Self-Antigens (Collagen Iv, Fibronectin, Perlecan) Predicts Progression of Chronic Immune Injury in Kidney Transplant Recipients
R. Ravichandran¹, Y. Itabashi¹, R. Heilman², A. Jaramillo², D. Ramon², M. Buras², B. Kaplan³, T. Mohanakumar¹, S. Sukumaran Nair²
¹St. Joseph’s Hospital, Phoenix, AZ, ²Mayo Clinic, Phoenix, AZ, ³Baylor Scott and White, Georgetown, TX
*Purpose: We have shown that circulating exosome with lung self-antigens (SAgs) are detectable 1 year prior to chronic lung allograft dysfunction, independent of circulating antibodies.…